Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962ZP1 (U.S. Pat. App. Aug. 30, 2018)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962ZP1 (U.S. Pat. App. Aug. 30, 2018)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962YP1 (U.S. Pat. App. Aug. 30, 2018)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962YP1 (U.S. Pat. App. Aug. 30, 2018)
+ More Snippets
Document
ELIQUIS, 202155, Letter (Orange Book Feb. 9, 2018)
Cite Document
ELIQUIS, 202155, Letter (Orange Book Feb. 9, 2018)
+ More Snippets
Document
ELIQUIS, 202155, Label (Orange Book Feb. 9, 2018)
Cite Document
ELIQUIS, 202155, Label (Orange Book Feb. 9, 2018)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962WP1 (U.S. Pat. App. Jul. 13, 2018)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962WP1 (U.S. Pat. App. Jul. 13, 2018)
+ More Snippets
Document
ELIQUIS, 202155, Label (Orange Book Nov. 29, 2017)
Cite Document
ELIQUIS, 202155, Label (Orange Book Nov. 29, 2017)
+ More Snippets
Document
ELIQUIS, 202155, Letter (Orange Book Nov. 29, 2017)
Cite Document
ELIQUIS, 202155, Letter (Orange Book Nov. 29, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962VP1 (U.S. Pat. App. May. 21, 2018)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962VP1 (U.S. Pat. App. May. 21, 2018)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-3-US-1357979632P1 (U.S. Pat. App. Jan. 16, 2019)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-3-US-1357979632P1 (U.S. Pat. App. Jan. 16, 2019)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962UP1 (U.S. Pat. App. May. 9, 2018)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962UP1 (U.S. Pat. App. May. 9, 2018)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962SP1 (U.S. Pat. App. May. 9, 2018)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962SP1 (U.S. Pat. App. May. 9, 2018)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962TP1 (U.S. Pat. App. May. 9, 2018)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962TP1 (U.S. Pat. App. May. 9, 2018)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962RP1 (U.S. Pat. App. May. 8, 2018)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962RP1 (U.S. Pat. App. May. 8, 2018)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-3-US-135797962QP1 (U.S. Pat. App. May. 8, 2018)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-3-US-135797962QP1 (U.S. Pat. App. May. 8, 2018)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962PP1 (U.S. Pat. App. May. 8, 2018)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962PP1 (U.S. Pat. App. May. 8, 2018)
+ More Snippets